Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Significant Survival Benefit of Novel Drugs in Post-Transplantation Relapse
- 1 December 2009
- journal article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 9 (6), 436-442
- https://doi.org/10.3816/clm.2009.n.086
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321Journal of Clinical Oncology, 2006
- High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-AutogreffeJournal of Clinical Oncology, 2005
- High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMABlood, 2005
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaThe New England Journal of Medicine, 2003
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaThe New England Journal of Medicine, 1996
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975